BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

VolverVolver

Resultados 64 resultados LastUpdate Última actualización 29/11/2022 [13:05:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



previousPage Página2 de 3 nextPage   por página


ANTIBODIES RECOGNIZING TAU

NºPublicación: JP2022169598A 09/11/2022

Solicitante:

プロセナバイオサイエンシーズリミテッド

UA_124148_PA

Resumen de: WO2017191560A1

The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

traducir

MODIFIED IMMUNOGLOBULINS FOR TARGETING AMYLOID DEPOSITS

NºPublicación: CN115298214A 04/11/2022

Solicitante:

田纳西大学研究基金会阿特拉斯公司

BR_112022009273_PA

Resumen de: WO2021097360A1

Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.

traducir

AMYLOID BETA DETECTION BY MASS SPECTROMETRY

NºPublicación: US2022349897A1 03/11/2022

Solicitante:

QUEST DIAGNOSTICS INVEST LLC [US]

JP_2021192038_A

Resumen de: US2022349897A1

Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.

traducir

Methods for quantification of amyloid beta peptides in plasma by mass spectrometry

NºPublicación: AU2021262526A1 03/11/2022

Solicitante:

ARACLON BIOTECH SL

WO_2021219917_A1

Resumen de: AU2021262526A1

The present invention relates to a method for preparing a plasma sample comprising amyloid beta peptides for analysis by mass spectrometry, comprising the steps of: a) placing said plasma sample in contact with a denaturing agent, b) performing a first solid phase extraction step on the solution obtained in step a) to recover a first eluate, c) performing a second solid phase extraction step on said first eluate obtained in step b) to recover a second eluate, and d) drying said second eluate obtained in step c) and processing it for analysis by mass spectrometry, wherein the solution obtained in step d) comprises intact amyloid beta peptides Aß40 and Aß42.

traducir

Therapeutic Agents, Pharmaceutical Compositions, and Associated Biomarkers based on Trk-B

NºPublicación: AU2021248268A1 03/11/2022

Solicitante:

INST DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
UNIV DE COIMBRA
FACULDADE DE MEDICINA DA UNIV DE LISBOA

WO_2021201710_A1

Resumen de: AU2021248268A1

Therapeutic Agents, Pharmaceutical Compositions, and Associated Biomarkers The invention relates to the identification of pharmaceutical compositions, therapeutic agents, peptides, nucleic acids, genetic constructs, vectors, cells, and medicaments, and their use in methods of treatment. For example, the treatment of neuropathological conditions, in particular Alzheimer's disease. Furthermore, provided herein are biomarkers, methods for their use, methods of diagnosis, methods of monitoring disease progression, and methods for monitoring medicament efficacy, in particular for Alzheimer's disease.

traducir

METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE SPECTRUM NEUROCOGNITIVE DISORDERS FROM TEAR SAMPLE, AND SOLUTION AND DIAGNOSTIC KIT USEFUL IN THE METHOD

NºPublicación: EP4081797A2 02/11/2022

Solicitante:

UNIV SZEGEDI [HU]

WO_2021130508_A2

Resumen de: WO2021130508A2

The invention relates to an aqueous solution of AuCl3x2H2O or HAuCl4x4H2O, ZnCI2 or ZnSO4, and AgNO3 having an Au3+ concentration of 0.8 mM-1.6 mM, a Zn2+ concentration of 15 μΜ-50 μΜ, and an Ag+ concentration of 5 μΜ-50 μΜ. The invention extends to a kit comprising a solution of the invention, a method of preparing said solution, and the use of a solution of the invention, a solution prepared by a method of the invention, or a kit of the invention in predicting and/or diagnosing and/or monitoring a neurocognitive disorder of the Alzheimer's disease spectrum. The invention extends to a method for predicting and/or diagnosing and/or monitoring a neurocognitive disorder of the Alzheimer's disease spectrum in a patient comprising contacting a tear sample from the patient normalised for protein concentration with a solution of the invention; applying an amount of the tear sample thus obtained to a surface; allowing the tear sample to dry; and drawing a conclusion based on the pattern of the thus obtained dried tear sample, whether the patient is at risk of or suffers from a neurocognitive disorder of the Alzheimer's disease spectrum.

traducir

SYSTEMS AND METHODS OF DETECTING A RISK OF ALZHEIMER'S DISEASE USING A CIRCULATING-FREE MRNA PROFILING ASSAY

NºPublicación: IL296574A 01/11/2022

Solicitante:

MOLECULAR STETHOSCOPE INC [US]

AU_2021236680_PA

Resumen de: WO2021188825A1

Disclosed herein are panels related to the diagnosis of diseased tissue in a subject. The disclosed panels and related methods are used to predict or assess whether a subject has a neurodegenerative disorder taking into account the age of the subject. Some embodiments of the methods include applying a gene filter based on the age of the subject and generating an output of gene expression data which takes into account differences in gene profiles seen in tissues as they age.

traducir

METHODS FOR QUANTIFICATION OF AMYLOID BETA PEPTIDES IN PLASMA BY MASS SPECTROMETRY

NºPublicación: CO2022014327A2 31/10/2022

Solicitante:

ARACLON BIOTECH SL [ES]

AU_2021262526_PA

Resumen de: WO2021219917A1

The present invention relates to a method for preparing a plasma sample comprising amyloid beta peptides for analysis by mass spectrometry, comprising the steps of: a) placing said plasma sample in contact with a denaturing agent, b) performing a first solid phase extraction step on the solution obtained in step a) to recover a first eluate, c) performing a second solid phase extraction step on said first eluate obtained in step b) to recover a second eluate, and d) drying said second eluate obtained in step c) and processing it for analysis by mass spectrometry, wherein the solution obtained in step d) comprises intact amyloid beta peptides Aß40 and Aß42.

traducir

METHODS AND COMPOSITIONS FOR MONITORING PHAGOCYTIC ACTIVITY

NºPublicación: US2022341948A1 27/10/2022

Solicitante:

INVEN2 AS [NO]

ES_2628596_T3

Resumen de: US2022341948A1

The invention relates to compositions and methods for monitoring phagocytic activity (e.g., diseases and conditions relating to phagocytic activity). In particular, the invention relates to compositions and methods for diagnosing, monitoring, and/or assessing risk of neurodegenerative diseases (e.g., AD).

traducir

Systems and methods of detecting a risk of Alzheimer's disease using a circulating-free mRNA profiling assay

NºPublicación: AU2021236680A1 27/10/2022

Solicitante:

MOLECULAR STETHOSCOPE INC

WO_2021188825_A1

Resumen de: AU2021236680A1

Disclosed herein are panels related to the diagnosis of diseased tissue in a subject. The disclosed panels and related methods are used to predict or assess whether a subject has a neurodegenerative disorder taking into account the age of the subject. Some embodiments of the methods include applying a gene filter based on the age of the subject and generating an output of gene expression data which takes into account differences in gene profiles seen in tissues as they age.

traducir

CERAMIDE AND SPHINGOMYELIN IN NEUROLOGICAL DISORDERS

NºPublicación: WO2022226427A2 27/10/2022

Solicitante:

UNIV DUKE [US]
METABOLOMICS LABORATORY [AU]
METABOLOMICS LABORATORY BAKER HEART & DIABETES INST [AU]
UNIV OF TX HEALTH CENTER AT SAN ANTONIO [US]
UNIV OF TEXAS HEALTH CENTER AT SAN ANTONIO [US]
INDIANA UNIV [US]
INDIANA ALZHEIMER DISEASE CENTER AND DEPT OF RADIOLOGY AND IMAGING SCIENCES [US]
SUNY DOWNSTATE MEDICAL CENTER [US]
INST SYSTEMS BIOLOGY [US]
INST OF COMPUTATIONAL BIOLOGY [DE]
HELMHOLTZ ZENTRUM MUNCHEN GERMAN RES CENTER FOR ENVIRONMENTAL HEALTH [DE]
KADDURAH DAOUK RIMA [US]
LOUIE GREGORY [US]
ARNOLD MATTHIAS [DE]
BAILLE REBECCA [US]
MEIKLE PETER [AU]
HAN XIANLIN [US]
SAYKIN ANDREW [US]
NHO NHO KWANGSIK [US]
MORENO HERMAN W [US]
FUNK CORY [US]
BALONI PRIYANKA [US]
KASTENMUELLER GABI [DE]

WO_2022226280_PA

Resumen de: WO2022226427A2

Described herein are compositions and methods for assessing and modulating ceramide and sphingomyelin in neurological disorders.

traducir

CERAMIDE AND SPINGOMYELIN IN NEUROLOGICAL DISORDERS

NºPublicación: WO2022226280A1 27/10/2022

Solicitante:

UNIV DUKE [US]
METABOLOMICS LABORATORY BAKER HEART & DIABETE INST [AU]
UNIV OF TEXAS HEALTH CENTER AT SAN ANTONIO [US]
INDIANA ALZHEIMER DISEASE CENTER AND DEPT OF RADIOLOGY AND IMAGINING SCIENCES [US]
SUNY DOWNSTATE MEDICAL CENTER [US]
INST SYSTEMS BIOLOGY [US]
HELMHOLTZ ZENTRUM MUNCHEN GERMAN RES CENTER FOR ENVIRONMENTAL HEALTH [DE]

WO_2022226427_PA

Resumen de: WO2022226280A1

Described herein are compositions and methods for assessing and modulating ceramide and sphingomyelin in neurological disorders.

traducir

METHOD OF INCREASING CHAPERONE MEDIATED AUTOPHAGY BY STABILIZING THE INTERACTION OF RETINOIC ACID RECEPTOR-ALPHA AND AN INHIBITOR

NºPublicación: WO2022226187A1 27/10/2022

Solicitante:

ALBERT EINSTEIN COLLEGE OF MEDICINE [US]

Resumen de: WO2022226187A1

This disclosure provides a method of stabilizing the interaction of a Retinoic Acid Receptor- alpha (RARα) and a corepressor, Nuclear Receptor Corepressor 1 (NCoRl) by contacting the RARa with an amount of a Chaperone Mediated Autophagy (CMA) Activator sufficient to stabilize the RARα-NCoRl interaction. Stabilizing the RARa/ corepressor interaction can prevent a neurodegenerative disorder in a subject at risk for developing the neurodegenerative disorder or slow the advancement of a neurodegenerative disorder in a subject having an early symptom or biomarker of the neurodegenerative disorder. The disclosure also provides a method of maintaining preventing or slowing the advancement of a retinal degenerative disorder in a subject having an early symptom or biomarker of the retinaldegenerative disorder. The neurodegenerative disorder can be Alzheimer's disease (AD),Lewy body dementia, Parkinson's disease (PD), Huntington's disease,.Amyotrophic lateralsclerosis (ALS), Frontotemporal dementia (FTD), Spinocerebellar ataxias (SCAs). The retinal degenerative disorder can be retinitis pigmentosa.

traducir

A BIOMARKER FOR ALZHEIMER'S DISEASE USING BLOOD SAMPLES FROM CLINICALLY DIAGNOSED ALZHEIMER'S DISEASE SUBJECTS

NºPublicación: JP2022545153A 26/10/2022

Solicitante:

トドスメディカルリミテッド・カンパニー

US_2022260595_A1

Resumen de: WO2021005568A1

The current invention discloses a method for diagnosing Alzheimer disease by using biomarkers, and multivariate analysis which gives a more reliable, minimally- or non-invasive method of detection. The invention discloses simultaneous detection of CD69 protein in mitogenic lymphocytes, tau and phosphorylated tau proteins, and amyloid-β peptides in cerebrospinal fluid, which can replace or supplement conventional methods of detection of Alzheimer's disease such as cognitive testing and amyloid-positron emission tomography.

traducir

HERV INHIBITORS FOR USE IN TREATING TAUOPATHIES

NºPublicación: US2022332799A1 20/10/2022

Solicitante:

DEUTSCHES ZENTRUM FUER NEURODEGENERATIVE ERKRANKUNGEN E V DZNE [DE]

WO_2021044009_A1

Resumen de: US2022332799A1

The present invention relates to inhibitors of HERV proteins comprising HERV Env and/or Gag, or fragments thereof, for use in treating a tauopathy, Parkinson's disease, or ALS (Amyothrophic Lateral Sclerosis). The present invention further relates to inhibitors of receptors which bind HERV Env proteins for use in treating a tauopathy, Parkinson's disease, or ALS (Amyothrophic Lateral Sclerosis). The present invention further relates to molecules binding to HERV Env and/or Gag, or fragments thereof, or to a nucleic acid molecule encoding said HERV Env and/or Gag, or fragments thereof, for use in diagnosing a tauopathy, Parkinson's disease, or ALS.

traducir

DIGITAL PROTEIN MISFOLDING ASSAYS

NºPublicación: WO2022221876A1 20/10/2022

Solicitante:

BRIGHAM & WOMENS HOSPITAL INC [US]

Resumen de: WO2022221876A1

Described herein are quantitative methods that can be used for diagnosis of neurodegenerative diseases, characterized partially by pathological protein aggregation and/or deposition, comprised of assaying in microwells, droplets, beads or some other support, the ability of a pathological protein in a biological sample to seed the conversion of substrate monomers into aggregated fibrils.

traducir

APPLICATION OF TPK AS A TARGET IN ALZHEIMER'S DISEASE

NºPublicación: US2022330531A1 20/10/2022

Solicitante:

SHANGHAI RAISING PHARMACEUTICAL CO LTD [CN]

JP_2022542520_PA

Resumen de: US2022330531A1

Provided is use of thiamine pyrophosphokinase TPK as a target in the treatment of Alzheimer's disease; and AD symptoms due to the inhibited TPK can be prevented by promoting the kinase activity and/or expression level of TPK protein in brain with TPK as a target.

traducir

METHODS TO DETECT MTBR TAU ISOFORMS AND USE THEREOF

NºPublicación: JP2022544514A 19/10/2022

Solicitante:

ワシントン・ユニバーシティ

US_2022299527_A1

Resumen de: WO2021030615A1

The methods disclosed herein employ unique combinations of processing steps that transform a blood or CSF sample into a sample suitable for quantifying MTBR tau species, as well as other tau species. The present disclosure also encompasses the use of MTBR tau species in blood or CSF to measure pathological features and/or clinical symptoms of 3R- and 4R- tauopathies in order to diagnose, stage, and/or choose treatments appropriate for a given disease stage, and modify a given treatment regimen.

traducir

QUANTIFICATION OF SUBPOPULATIONS OF EXOSOMES AND DIAGNOSIS OF NEURODEGENERATIVE DISORDERS

NºPublicación: JP2022160422A 19/10/2022

Solicitante:

ナノソミックス・インコーポレイテッド

JP_2020500309_A

Resumen de: WO2018094120A1

The present invention relates to methods for quantifying subpopulations of exosomes and diagnostic and prognostic methods for neurodegenerative disorders (e.g., Alzheimer's disease). The invention also provides compositions for quantifying subpopulations of exosomes as well as compositions and methods useful for treating Alzheimer's disease and other neurodegenerative disorders.

traducir

Somatic expansion inhibitors

NºPublicación: GB2605845A 19/10/2022

Solicitante:

UCL BUSINESS LTD [GB]
CAMBRIDGE ENTPR LTD [GB]

Resumen de: GB2605845A

A composition for use in treating a repeat expansion disease comprising an MLH1 inhibitor and/or a FAN1 derived nuclease. The repeat expansion disease may include Huntington’s disease, Fragile X Syndrome, myotonic dystrophy (DM1 and DM2), amyotrophic lateral sclerosis and/or frontotemporal dementia caused by somatic expansion in the C9ORF72 gene, spinocerebellar ataxias (SCAs 1, 2, 3, 6, 7 and 17), Friedreich’s ataxia (FRDA), Fragile X Tremor Ataxia Syndrome (FXS/FXTAS), dentatorubral-pallidoluysian atrophy (DRPLA), spinal and bulbar muscular atrophy (SBMA), and Unverricht-Lundborg myoclonic epilepsy (EPM1). The MLH1 inhibitor may be a cyclic peptide, a peptide comprising the amino acid sequence SPYF, or a peptide having at least 70% identity to residues 120-140, 73-165, 73-190, 73-349, 1-165, 1-190 or 1-349 of SEQ ID NO.2. Also claimed is a method of identifying MLH1 inhibitors comprising culturing cells expressing MLH1 and MSH3 in the presence of a test agent, purifying MLH1 and proteins bound thereto, determining the level of MSH3 bound to MLH1 and comparing to a control level in the absence of the test agent.

traducir

DETECTION METHOD OF CIRCULATING BMP10 (BONE MORPHOGENETIC PROTEIN 10)

NºPublicación: CN115190886A 14/10/2022

Solicitante:

马斯特里赫特大学马斯特里赫特大学医学中心豪夫迈·罗氏有限公司

WO_2021165465_A1

Resumen de: WO2021165465A1

The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.

traducir

COMPOSITION, FORMULATIONS AND METHODS OF MAKING AND USING BOTANICALS AND NATURAL COMPOUNDS FOR THE PROMOTION OF HEALTHY BRAIN AGING

NºPublicación: US2022323464A1 13/10/2022

Solicitante:

THE BRAIN HEALTH PROJECT LLC [US]

US_2022117979_A1

Resumen de: US2022323464A1

The present disclosure provides compositions and formulations comprising botanicals and natural compounds for the promotion of healthy brain aging in adults, especially adult women, and for prevention of age associated neurodegenerative changes resulting in cognitive, memory and executive dysfunction including modulation of the age related predisposition to mild cognitive impairment, Alzheimer's disease, hormonal and other dementia related conditions. The present disclosure also provides methods of using the compositions and formulations in treating and preventing neurodegenerative changes resulting in cognitive, memory and executive dysfunction.

traducir

IN VITRO DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE BASED ON THE ALBUMIN REDOX LEVEL IN THE CEREBROSPINAL FLUID

NºPublicación: US2022326259A1 13/10/2022

Solicitante:

GRIFOLS WORLDWIDE OPERATIONS LTD [IE]

US_2020141951_A1

Resumen de: US2022326259A1

An in vitro method for diagnosing Alzheimer's disease (AD) includes determining the content of mercaptoalbumin (HMA) in a sample of cerebrospinal fluid (CSF), and comparing the content determined with the content of HMA in CSF in healthy subjects. If the HMA content is less than that of the healthy subjects, it is indicative of AD.

traducir

GENETIC VARIANTS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE

NºPublicación: US2022325347A1 13/10/2022

Solicitante:

UNIV HONG KONG SCIENCE & TECH [CN]

CN_114568028_PA

Resumen de: US2022325347A1

The present invention provides genetic markers associated with the Alzheimer's Disease (AD), diagnostic and treatment methods for AD, and kits for diagnosing AD.

traducir

CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER'S DISEASE

Nº publicación: WO2022214717A1 13/10/2022

Solicitante:

FUNDACIO ACE INST CATALA DE NEUROCIENCIES APLICADES [ES]
UNIV KOELN [DE]

EP_4071480_PA

Resumen de: WO2022214717A1

The present invention relates to a new biomarkers for the diagnosis of Alzheimer's disease (AD). More specifically, the present invention relates to the predictive detection of Alzheimer's disease (AD) in a mammal. The biomarkers, methods and kits provided enable prediction of progressions of Mild cognitive impairment (MCI) to AD by measurement of biomarkers in biological fluids that will provide an indication of whether a subject is likely to develop a neurological disease, such as Alzheimer's disease (AD).

traducir

previousPage Página2 de 3 nextPage por página

punteroimgVolver